Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Pansalb’s Language Rights Monitor Project launched at the UFS
2007-01-25

 

 Attending the launch of the Language Rights Monitoring Project were, from the left: Mr Edward Sambo (acting head of Pansalb), Prof Engela Pretorius (Vice-Dean of the Faculty of the Humanities at the UFS), Prof Theo du Plessis (Director: Unit for Language Management at the UFS) and Mr Vusi Ntlakana (head of the Free State provincial office of Pansalb).

 
 Pansalb’s Language Rights Monitor Project launched at the UFS
 
The Unit for Language Management at the University of the Free State (UFS), in collaboration with the Pan-South African Language Board (Pansalb), today launched the Language Rights Monitor Project on the Main Campus in Bloemfontein.
 
In accordance with the Pansalb Act of 1995, Pansalb is responsible for the promotion and protection of language rights in South Africa, and is the chief funder of the project.          
 
The Language Rights Monitor Project was initiated in 2002 for a trial period of three years, with the aim of reporting to Pansalb, on an annual basis, on language-rights issues in South Africa, as reflected mainly in the printed media.
 
Since then, three reports have already appeared, covering various aspects relating to language rights, including, inter alia, language-rights complaints, language-rights issues, language litigation, as well as research on language rights in South Africa. Profs Johan Lubbe and Theo du Plessis, as well as Dr Elbie Truter, all associated to the UFS, were responsible for the compilation of the first three reports.
 
During 2006, Pansalb decided to establish the project for an unspecified period of time at the Unit for Language Management at the UFS. It is precisely for this reason that the project is being launched. The South African Language Rights Monitor will henceforth appear annually as a prestige publication of Pansalb, compiled by staff associated with the Unit.
 
However, Pansalb has also decided to further consolidate the project, as a result of the need for a more immediate report, as well as the need to include records drawn from newspapers published in the African languages. It was therefore decided that, as from September 2006, a monthly South African Language Rights Bulletin would also be launched. 
 
Such a bulletin would provide an overview, on a monthly basis, of developments in South Africa concerning language rights, and would enable Pansalb to become more actively involved in crisis situations in which mediation is urgently needed. Two monthly bulletins have already appeared, and were favourably received by Pansalb. During the launch of the project, this bulletin was also introduced to the public for the first time.
 
With the official launch of Pansalb’s Language Rights Monitor project in the Free State, emphasis will be placed on the leading role played by this province, and more specifically by the UFS, in the development and implementation of a multilingual policy.
 
In future, more information on the situation regarding language-rights issues in South Africa will be made available from Bloemfontein, for the benefit of South Africa’s language-rights watchdog, Pansalb, but also for the benefit of other institutions involved in language-rights issues.
 
A constructive contribution will thus be rendered to the cultivation of language justice, an important element of the democratisation process in South Africa.
 
Issued by:
Prof Theo du Plessis
Unit for Language Management, UFS
 
 
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
24 January 2007

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept